Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Glaxosmithkline Plc (GSK)

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,502,768
  • Shares Outstanding, K 2,508,520
  • Annual Sales, $ 43,100 M
  • Annual Income, $ 5,931 M
  • 60-Month Beta 0.67
  • Price/Sales 2.20
  • Price/Cash Flow 8.81
  • Price/Book 3.59
Trade GSK with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.62
  • Number of Estimates 2
  • High Estimate 0.68
  • Low Estimate 0.55
  • Prior Year 0.64
  • Growth Rate Est. (year over year) -3.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.80 +7.46%
on 12/21/20
38.67 -0.51%
on 01/06/21
+1.65 (+4.48%)
since 12/15/20
3-Month
33.26 +15.66%
on 10/30/20
39.26 -2.02%
on 11/11/20
+2.49 (+6.92%)
since 10/15/20
52-Week
31.43 +22.40%
on 03/23/20
48.25 -20.27%
on 01/24/20
-9.14 (-19.20%)
since 01/15/20

Most Recent Stories

More News
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals

Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.

SNY : 49.39 (+0.73%)
RHHBY : 44.5600 (+1.39%)
PFE : 36.70 (-0.14%)
MRK : 83.38 (+1.47%)
LLY : 190.77 (+2.19%)
GSK : 38.47 (+0.81%)
NVS : 95.63 (+1.07%)
Huntington's Disease Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The research report titled Huntington's Disease Therapeutics offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product...

APHB : 0.32 (-20.33%)
CORX : 1.0200 (+385.71%)
GSK : 38.47 (+0.81%)
PRAN : 2.06 (unch)
RPTP : 9.00 (unch)
VRX.TO : 30.80 (-3.33%)
VRTX : 225.55 (-0.25%)
Antibiotics Market to Reach USD 39.06 Billion by 2027 at 2.1% CAGR; Surging Cases of Bacterial Infections to Incite Development, states Fortune Business Insights(TM)

The global antibiotics market size is expected to reach USD 39.06 billion in 2027 at a CAGR of 2.1% during the forecast period. The increasing R&D for the development of antimicrobials in multidrug-resistant...

DSNKY : 35.3800 (-0.53%)
GSK : 38.47 (+0.81%)
MRK : 83.38 (+1.47%)
Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.

ALXN : 156.70 (+0.03%)
PFE : 36.70 (-0.14%)
MRK : 83.38 (+1.47%)
GSK : 38.47 (+0.81%)
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

GILD : 63.33 (+1.49%)
GSK : 38.47 (+0.81%)
ALNY : 166.36 (+0.78%)
VIR : 39.31 (+7.73%)
Insights on the Typhoid Fever Vaccines APAC Market to 2027 - by Vaccine Type, Route of Administration and Country

, /PRNewswire/ -- The report has been added to offering.

GSK : 38.47 (+0.81%)
Global Asthma Drug Forecast to 2029 - GlaxoSmithKline and AstraZeneca Lead the Way

, /PRNewswire/ -- The report has been added to offering.

GSK : 38.47 (+0.81%)
Gilead (GILD) Ups Revenue Guidance on Increased Veklury Demand

Gilead (GILD) lifts guidance for 2020, driven by increased Veklury (remdesivir) sales for COVID-19 as the pandemic worsens.

NVO : 72.03 (+1.41%)
GILD : 63.33 (+1.49%)
GSK : 38.47 (+0.81%)
GLPG : 100.01 (-1.68%)
Post-Operative Pain Management Market Overview: Type and Applications, Trends, Industry Analysis & Forecast, 2018-2023

BAX : 80.04 (-0.01%)
LLY : 190.77 (+2.19%)
ENDP : 7.12 (-1.39%)
FRX : 10.47 (-6.85%)
GSK : 38.47 (+0.81%)
NVS : 95.63 (+1.07%)
VRX.TO : 30.80 (-3.33%)
Hemifacial Spasm Market 2021 Global Analysis, Size, Growth, Leading Players, Merger, Acquisition, Opportunity, With Regional Outlook To 2023

AGN : 193.02 (+0.02%)
GSK : 38.47 (+0.81%)
NVS : 95.63 (+1.07%)
RVNC : 28.64 (-0.69%)
SHPG : 179.20 (+4.10%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Key Turning Points

3rd Resistance Point 39.13
2nd Resistance Point 38.90
1st Resistance Point 38.68
Last Price 38.47
1st Support Level 38.23
2nd Support Level 38.00
3rd Support Level 37.78

See More

52-Week High 48.25
Fibonacci 61.8% 41.82
Fibonacci 50% 39.84
Last Price 38.47
Fibonacci 38.2% 37.86
52-Week Low 31.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar